SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
1-Year Return
18.23%
This Quarter Return
+14.15%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$736M
AUM Growth
+$112M
(+18%)
Cap. Flow
+$80.4M
Cap. Flow
% of AUM
10.92%
Top 10 Holdings %
Top 10 Hldgs %
43.9%
Holding
92
New
21
Increased
19
Reduced
26
Closed
16
Top Buys
| 1 |
Illumina
ILMN
|
$28.9M |
| 2 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$28.5M |
| 3 |
Eli Lilly
LLY
|
$26.1M |
| 4 |
Charles River Laboratories
CRL
|
$25.4M |
| 5 |
Envista
NVST
|
$15.7M |
Top Sells
| 1 |
Viridian Therapeutics
VRDN
|
$16.8M |
| 2 |
AnaptysBio
ANAB
|
$14.8M |
| 3 |
AngioDynamics
ANGO
|
$13M |
| 4 |
United Therapeutics
UTHR
|
$12.7M |
| 5 |
APEN
Apollo Endosurgery, Inc.
APEN
|
$11.7M |
Sector Composition
| 1 | Healthcare | 92.93% |
| 2 | Consumer Staples | 4.27% |
| 3 | Financials | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMGO
51
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
| $3.21M | 0.44% |
+213,000
| New | +$3.21M |
|
52
FibroGen
FGEN
$45.7M
| $3.05M | 0.41% |
9,361
-2,728
| -23% | -$887K |
|
53
Lyra Therapeutics
LYRA
$11.6M
| $2.97M | 0.4% |
11,848
| – | – |
|
54
Mirum Pharmaceuticals
MIRM
$3.73B
| $2.85M | 0.39% |
135,618
-60,400
| -31% | -$1.27M |
|
55
OraSure Technologies
OSUR
$230M
| $2.14M | 0.29% |
+565,000
| New | +$2.14M |
|
56
InMode
INMD
$911M
| $1.96M | 0.27% |
67,449
-120,000
| -64% | -$3.49M |
|
57
DexCom
DXCM
$31.7B
| $1.92M | 0.26% |
23,836
-23,400
| -50% | -$1.88M |
|
58
89bio
ETNB
$1.28B
| $1.91M | 0.26% |
+330,000
| New | +$1.91M |
|
|
EIGR
59
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $1.65M | 0.22% |
7,300
-20,900
| -74% | -$4.72M |
|
|
60
AnaptysBio
ANAB
$590M
| $1.63M | 0.22% |
64,027
-579,548
| -90% | -$14.8M |
|
|
KDNY
61
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $1.53M | 0.21% |
78,000
-10,000
| -11% | -$197K |
|
62
Fate Therapeutics
FATE
$112M
| $1.51M | 0.2% |
67,300
-127,100
| -65% | -$2.85M |
|
63
CRISPR Therapeutics
CRSP
$4.8B
| $1.44M | 0.2% |
22,000
| – | – |
|
64
Novo Nordisk
NVO
$249B
| $1.41M | 0.19% |
+28,200
| New | +$1.41M |
|
65
Verastem
VSTM
$650M
| $1.4M | 0.19% |
137,042
| – | – |
|
66
Xilio Therapeutics
XLO
$37.2M
| $1.32M | 0.18% |
453,660
| – | – |
|
67
Y-mAbs Therapeutics
YMAB
$389M
| $1.26M | 0.17% |
87,182
-49,000
| -36% | -$706K |
|
68
PepGen
PEPG
$42M
| $1.18M | 0.16% |
130,000
-45,000
| -26% | -$408K |
|
69
Apellis Pharmaceuticals
APLS
$3.62B
| $915K | 0.12% |
+13,400
| New | +$915K |
|
70
IO Biotech
IOBT
$117M
| $781K | 0.11% |
288,119
-367,285
| -56% | -$996K |
|
71
Immunic
IMUX
$76M
| $758K | 0.1% |
240,000
| – | – |
|
|
DALS
72
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
| $487K | 0.07% |
50,000
| – | – |
|
73
Pliant Therapeutics
PLRX
$100M
| $443K | 0.06% |
21,200
-468,800
| -96% | -$9.8M |
|
74
Rocket Pharmaceuticals
RCKT
$349M
| $404K | 0.05% |
25,300
-292,800
| -92% | -$4.68M |
|
|
75
Viridian Therapeutics
VRDN
$1.52B
| $400K | 0.05% |
19,518
-821,500
| -98% | -$16.8M |
|